Investors

Sensei is a biopharmaceutical company engaged in the discovery, development, and delivery of next-generation immunotherapies for the treatment of cancer. The company is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases. The company’s research is dedicated to two immuno-oncology platforms: Tumor Microenvironment Antibody biologics, or TMAb™ platform and ImmunoPhage™ platform and Phortress™ library.

Sensei’s TMAb platform is comprised of human monoclonal antibodies and alpaca-derived nanobodies selectively active in the tumor microenvironment. The lead product candidate, SNS-101, is in preclinical studies targeting the novel immune checkpoint regulator V-set Immunoglobulin Domain Ig Suppressor or T cell activation, or VISTA. SNS-101 is a potent, pH-dependent fully human monoclonal antibody designed to block the interaction of VISTA with its receptor, PSGL-1. Discovery efforts are also underway directed toward the V-Set And Immunoglobulin Domain Containing 4, or VSIG4, a potent inhibitor of T cell activity, often overexpressed on macrophages within the tumor microenvironment.

Sensei’s proprietary ImmunoPhage platform leverages the self-adjuvanted and highly immunogenic properties of engineered bacteriophage. This platform allows Sensei to develop novel therapeutics that target key mechanisms of checkpoint resistance to induce a robust, focused and coordinated immune response. The program includes SNS-401-NG, a preclinical candidate for the treatment of Merkel cell carcinoma